Long Non-coding RNA FOXD2-AS1 Serve as a Potential Prognostic Biomarker for Patients with Cancer: A Meta-analysis and Database Testing

ABSTRACT Background : The aim of this study is to summarize the current findings concerning the FOXD2-AS1 expression and cancer prognosis. Methods : The correlation intensity between FOXD2-AS1 expression and cancer prognosis was estimated using pooled hazard ratio (HRs) with 95% confidence intervals (CIs). GEPIA was used to assess disease-free survival (DFS), progression-free surbival (PFS) and overall survival (OS) of cancer patients and differential FOXD2-AS1 expression in cancer and adjacent tissues. Results : A total of 11 studies including 2,177 patients with OS and 477 patients with DFS/PFS data were analyzed in evidence synthesis. Overall, the pooled analysis indicated that FOXD2-AS1 expression was significantly associated with OS (HR=1.51, 95%Cl: 1.26–1.81, P Conclusions : Our findings indicated that FOXD2-AS1 may serve as a potential independent prognostic factor in cancer, especially in the Chinese population.